Manufacturer record
M/.s Digital Vision: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by M/.s Digital Vision (Himachal Pradesh) was declared Not of Standard Quality in August 2024. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: NTD0203, Escitalopram and Clonazepam Tablets IP (Klozaps-ES Tablets) (exp Nov 2025). RDTL Chandigarh (CDSCO lab) found it not of standard quality: Assay of Escitalopram Oxalate calculated as Escitalopram and Clonazepam. Listed in the August 2024 alert.
Records by type
1 record linked to M/.s Digital Vision in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Escitalopram and Clonazepam Tablets IP (Klozaps-ES Tablets) | Batch NTD0203Mfg Dec 2023 · Exp Nov 2025 | Assay of Escitalopram Oxalate calculated as Escitalopram and ClonazepamAssay | RDTL ChandigarhCDSCO lab | Aug 2024 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.